Castleark Management LLC Cuts Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Castleark Management LLC reduced its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 4.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 52,360 shares of the company’s stock after selling 2,260 shares during the quarter. Castleark Management LLC’s holdings in Vaxcyte were worth $4,286,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of PCVX. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Vaxcyte by 15.8% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 472,964 shares of the company’s stock valued at $38,717,000 after acquiring an additional 64,690 shares during the period. Windsor Advisory Group LLC lifted its position in Vaxcyte by 72.5% in the fourth quarter. Windsor Advisory Group LLC now owns 39,223 shares of the company’s stock valued at $3,211,000 after purchasing an additional 16,479 shares during the last quarter. Woodline Partners LP lifted its position in Vaxcyte by 1.5% in the fourth quarter. Woodline Partners LP now owns 1,120,922 shares of the company’s stock valued at $91,759,000 after purchasing an additional 16,977 shares during the last quarter. Soleus Capital Management L.P. boosted its stake in shares of Vaxcyte by 266.2% during the fourth quarter. Soleus Capital Management L.P. now owns 99,050 shares of the company’s stock valued at $8,108,000 after purchasing an additional 72,000 shares during the period. Finally, Twinbeech Capital LP bought a new position in shares of Vaxcyte in the fourth quarter worth approximately $22,916,000. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Analysts Set New Price Targets

PCVX has been the subject of a number of recent analyst reports. The Goldman Sachs Group lowered their price target on shares of Vaxcyte from $138.00 to $100.00 and set a “buy” rating for the company in a report on Tuesday, April 1st. Guggenheim restated a “buy” rating and issued a $160.00 price objective on shares of Vaxcyte in a research report on Wednesday, March 12th. Bank of America lowered their price objective on shares of Vaxcyte from $157.00 to $137.00 and set a “buy” rating for the company in a research note on Tuesday, April 1st. Evercore ISI raised Vaxcyte to a “strong-buy” rating in a research note on Monday, March 31st. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 price target on shares of Vaxcyte in a research report on Tuesday, April 8th. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $136.50.

Vaxcyte Price Performance

Shares of NASDAQ PCVX opened at $33.97 on Thursday. Vaxcyte, Inc. has a 1 year low of $27.66 and a 1 year high of $121.06. The stock has a market capitalization of $4.38 billion, a P/E ratio of -7.38 and a beta of 1.27. The company’s 50-day moving average is $40.20 and its 200 day moving average is $70.45.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same quarter last year, the company earned ($0.85) earnings per share. Research analysts anticipate that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Insider Activity

In related news, COO Jim Wassil sold 8,000 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $73.27, for a total value of $586,160.00. Following the completion of the transaction, the chief operating officer now directly owns 154,931 shares in the company, valued at $11,351,794.37. This trade represents a 4.91% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.10% of the stock is currently owned by company insiders.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.